Replies to post #173588 on Biotech Values

[biomaven0]

It has been noted that GILD has started an 8-week trial in cirrhotics both with and without riba. I think that is a signal that their 12 week data was pretty damn good.

Peter

[bladerunner1717]

You’ve neglected to realize that GILD’s Sovaldi + Ledipasvir regimen is de facto BID dosing for any subgroup in which ribavirin is used.

You've neglected the relapse issue and the possibility of eight week dosing.


Bladerunner